ABBVIE
🇫🇷France
A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: M200 (Volociximab), Carboplatin, Paclitaxel
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 33
- Registration Number
- NCT00654758
Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: adalimumab
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT00650156
- Locations
- 🇨🇳
Site Reference ID/Investigator# 7181, Shanghai, China
An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 155
- Registration Number
- NCT00619866
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
Phase 1
Completed
- Conditions
- Non-hematologic MalignanciesPrimary Peritoneal CancerHepatocellular CarcinomaMetastatic MelanomaOvarian CancerFallopian Tube CancerBreast Cancer
- Interventions
- Drug: ABT-888Drug: Temozolomide
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 41
- Registration Number
- NCT00526617
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 1
Completed
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Drug: ABT-263
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT00481091
- Locations
- 🇺🇸
Dana-Farber Cancer Institute /ID# 5547, Boston, Massachusetts, United States
🇬🇧Leicester Royal Infirmary /ID# 15081, Leicester, England, United Kingdom
🇺🇸Moores Cancer Center at UC San Diego /ID# 5566, La Jolla, California, United States
Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis
Phase 2
Completed
- Conditions
- Endometriosis
- Interventions
- Drug: ElagolixDrug: Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)Drug: Placebo to DMPA-SCDrug: Placebo to Elagolix
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 252
- Registration Number
- NCT00437658
© Copyright 2025. All Rights Reserved by MedPath